E
KYNB

Ergoteles’s Kyntra Bio KYNB Stock Holding History

Ergoteles’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,620
Closed -$756K – 1180
2023
Q1 		$756K Sell
1,620
-846
-34% -$448K 0.03% 600
2022
Q4 		$988K Sell
2,466
-1,592
-39% -$610K 0.04% 462
2022
Q3 		$1.32M Buy
4,058
+1,426
+54% +$459K 0.05% 389
2022
Q2 		$695K Buy
2,632
+298
+13% +$76.1K 0.02% 697
2022
Q1 		$701K Buy
2,334
+335
+17% +$117K 0.03% 545
2021
Q4 		$705K Buy
+1,999
New +$622K 0.03% 518

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's KYNB Position: Q2 2023 in Review

Ergoteles sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 1,620 shares — an estimated $756K sold.

Ergoteles first reported a position in KYNB in Q4 2021 and held it in 6 quarters. The position peaked at $1.32M in Q3 2022. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Ergoteles reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 1,620 Kyntra Bio shares in Q2 2023, an estimated $756K.
  • Ergoteles first reported a position in Kyntra Bio in Q4 2021 and held it in 6 quarters.
  • Ergoteles's Kyntra Bio position peaked at $1.32M in Q3 2022.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.